Related Experiment Video
Updated: Feb 24, 2026
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations
Gino K In1, James S Hu1, William W Tseng2
1Division of Oncology, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Abstract:
Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50 subtypes. Historically, there have been few systemic treatment options for this relatively rare disease. Traditional cytotoxic agents, such as anthracyclines, alkylating agents, and taxanes have limited clinical benefit beyond the first-line setting; across all high-grade STS subtypes, median overall survival remains approximately 12-18 months for advanced metastatic disease. The development of targeted therapies has led to recent US Food and Drug Administration approval of four new treatments for high-grade STS in the advanced metastatic setting. Among these, olaratumab is most notable for its improvement in overall survival for patients with anthracycline-naïve disease. Further progress in STS management will rely on novel trial design, subtype-specific therapies and validation of biomarkers to tailor therapy. Immunotherapy has shown promise as a new, but yet undiscovered frontier in the management of STS.
Insights
Soft tissue sarcoma (STS) is a rare cancer with limited treatment options. Recent advances include targeted therapies and olaratumab, improving survival for advanced disease, with immunotherapy showing future promise.
Area of Science:
- Oncology
- Medical Malignancies
Background:
- Soft tissue sarcoma (STS) is a heterogeneous cancer with over 50 subtypes.
- Limited systemic treatment options exist for advanced or metastatic STS.
- Traditional cytotoxic agents offer minimal benefit beyond first-line treatment.
Purpose of the Study:
- To review recent advancements in the systemic treatment of soft tissue sarcoma.
- To highlight novel therapies approved for advanced metastatic STS.
- To discuss future directions in STS management, including immunotherapy.
Main Methods:
- Review of current literature and recent clinical trial data.
- Analysis of approved targeted therapies for advanced STS.
- Discussion of emerging treatment modalities and biomarker validation.
Main Results:
- Four new targeted therapies have been approved for advanced metastatic STS.
- Olaratumab demonstrated improved overall survival in anthracycline-naïve patients.
- Current treatments show limited efficacy in the first-line setting for high-grade STS.
Conclusions:
- Progress in STS management requires novel trial designs and subtype-specific therapies.
- Biomarker validation is crucial for tailoring treatment strategies.
- Immunotherapy represents a promising, yet underexplored, frontier for STS treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...